Alkeon Capital Management
AGIO icon

Alkeon Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Alkeon Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-491,615
Closed -$26.3M – 146
2020
Q2 		$26.3M Hold
491,615
– – 0.07% 112
2020
Q1 		$17.4M Hold
491,615
– – 0.07% 110
2019
Q4 		$23.5M Sell
491,615
-295,000
-38% -$11.1M 0.09% 102
2019
Q3 		$25.5M Buy
786,615
+100,000
+15% +$4.14M 0.09% 104
2019
Q2 		$34.2M Hold
686,615
– – 0.14% 98
2019
Q1 		$46.3M Buy
686,615
+237,500
+53% +$13.8M 0.23% 88
2018
Q4 		$20.7M Sell
449,115
-244,839
-35% -$15.1M 0.13% 99
2018
Q3 		$53.5M Buy
693,954
+165
+0% +$13.3K 0.25% 76
2018
Q2 		$58.4M Buy
693,789
+25,000
+4% +$2.18M 0.27% 72
2018
Q1 		$54.7M Buy
668,789
+157,170
+31% +$12.1M 0.29% 70
2017
Q4 		$29.3M Buy
511,619
+54,858
+12% +$3.45M 0.17% 71
2017
Q3 		$30.5M Buy
+456,761
New +$27.4M 0.22% 73

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management's AGIO Position: Q3 2020 in Review

Alkeon Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 491,615 shares — an estimated $26.3M sold.

Alkeon Capital Management first reported a position in AGIO in Q3 2017 and held it in 12 quarters. The position peaked at $58.4M in Q2 2018. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

  • Alkeon Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Alkeon Capital Management sold 491,615 Agios Pharmaceuticals shares in Q3 2020, an estimated $26.3M.
  • Alkeon Capital Management first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 12 quarters.
  • Alkeon Capital Management's Agios Pharmaceuticals position peaked at $58.4M in Q2 2018.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Alkeon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.